KA2507, a potent, orally active and selective HDAC6 inhibitor with IC50 of 2.5 nM, shows antitumor activities and immune modulatory effects in preclinical models.
[1] Tsimberidou AM, et al. Clin Cancer Res. 2021 Jul 1;27(13):3584-3594.
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 5 mg | ¥3,150.00 | 现货 | 1 |
















KA2507, a potent, orally active and selective HDAC6 inhibitor with IC50 of 2.5 nM, shows antitumor activities and immune modulatory effects in preclinical models.
[1] Tsimberidou AM, et al. Clin Cancer Res. 2021 Jul 1;27(13):3584-3594.